-- BMB-101 is a highly selective and potent 5-HT 2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control ...
I specialize in advanced brain-based assessment and intervention, utilizing EEG, qEEG, and LORETA neuroimaging to identify dysregulated neural networks underlying cognitive, emotional, and behavioral ...
INDIANAPOLIS--(BUSINESS WIRE)--Gate Neurosciences, a clinical-stage biotechnology company using precision medicine approaches to develop next-generation neuroscience therapies, today announced ...
SP-624 has the potential to be the first treatment specifically for females with Major Depression MORRISVILLE, N.C.--(BUSINESS WIRE)-- Arrivo BioVentures today announced positive data from its ...
After Bright Minds Bioscience's DRUG announcement that its quantitative EEG garnered positive results, the company stock shot up 91% Tuesday morning, spiking to $6.18 from Monday's close of $3.23 per ...
-- In qEEG, BMB-101 demonstrated robust increase in central delta power and robust reduction in central alpha and beta power in active group, as previously reported for Anti-Epileptic Drugs (AEDs) in ...
MORRISVILLE, N.C.--(BUSINESS WIRE)--Arrivo BioVentures today announced positive data from its SP-624-103 study evaluating the impact of SP-624’s novel epigenetic mechanism of action on neurological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback